28093505|t|Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice
28093505|a|Erythropoietic protoporphyria (EPP) is caused by deficiency of ferrochelatase (FECH), which incorporates iron into protoporphyrin IX (PPIX) to form heme. Excitation of accumulated PPIX by light generates oxygen radicals that evoke excessive pain and, after longer light exposure, cause ulcerations in exposed skin areas of individuals with EPP. Moreover, ∼5% of the patients develop a liver dysfunction as a result of PPIX accumulation. Most patients (∼97%) have a severe FECH mutation (Mut) in trans to an intronic polymorphism (c.315-48C), which reduces ferrochelatase synthesis by stimulating the use of an aberrant 3' splice site 63 nt upstream of the normal site for exon 4. In contrast, with the predominant c.315-48T allele, the correct splice site is mostly used, and individuals with a T/Mut genotype do not develop EPP symptoms. Thus, the C allele is a potential target for therapeutic approaches that modify this splicing decision. To provide a model for pre-clinical studies of such approaches, we engineered a mouse containing a partly humanized Fech gene with the c.315-48C polymorphism. F1 hybrids obtained by crossing these mice with another inbred line carrying a severe Fech mutation (named m1Pas) show a very strong EPP phenotype that includes elevated PPIX in the blood, enlargement of liver and spleen, anemia, as well as strong pain reactions and skin lesions after a short period of light exposure. In addition to the expected use of the aberrant splice site, the mice also show a strong skipping of the partly humanized exon 3. This will limit the use of this model for certain applications and illustrates that engineering of a hybrid gene may have unforeseeable consequences on its splicing.
28093505	0	8	Modeling	T062	C0870071
28093505	13	37	ferrochelatase c.315-48C	T028	C1414580
28093505	47	55	mutation	T045	C0026882
28093505	60	89	erythropoietic protoporphyria	T047	C0162568
28093505	91	94	EPP	T047	C0162568
28093505	99	103	mice	T015	C0026809
28093505	104	133	Erythropoietic protoporphyria	T047	C0162568
28093505	135	138	EPP	T047	C0162568
28093505	153	163	deficiency	T080	C1623416
28093505	167	181	ferrochelatase	T116,T126	C0015880
28093505	183	187	FECH	T116,T126	C0015880
28093505	209	213	iron	T121,T123,T196	C0302583
28093505	219	236	protoporphyrin IX	T121	C0072497
28093505	238	242	PPIX	T121	C0072497
28093505	252	256	heme	T109,T123	C0018966
28093505	258	268	Excitation	T052	C0549255
28093505	284	288	PPIX	T121	C0072497
28093505	292	297	light	T070	C0023693
28093505	308	323	oxygen radicals	T123	C0178645
28093505	335	344	excessive	T080	C0442802
28093505	345	349	pain	T184	C0030193
28093505	361	382	longer light exposure	T051	C1689916
28093505	390	401	ulcerations	T047	C0041582
28093505	413	417	skin	T022	C1123023
28093505	427	438	individuals	T098	C0237401
28093505	444	447	EPP	T047	C0162568
28093505	470	478	patients	T101	C0030705
28093505	489	506	liver dysfunction	T046	C0086565
28093505	522	526	PPIX	T121	C0072497
28093505	527	539	accumulation	T033	C4055506
28093505	546	554	patients	T101	C0030705
28093505	576	580	FECH	T028	C1414580
28093505	581	619	mutation (Mut) in trans to an intronic	T045	C1881249
28093505	620	632	polymorphism	T045	C0678951
28093505	634	643	c.315-48C	T028	C1414580
28093505	660	674	ferrochelatase	T116,T126	C0015880
28093505	675	684	synthesis	T052	C1883254
28093505	688	699	stimulating	T070	C1948023
28093505	714	722	aberrant	T080	C0443127
28093505	723	737	3' splice site	T045	C1158733
28093505	738	771	63 nt upstream of the normal site	T086	C1710582
28093505	776	783	exon 4.	T114,T123	C0015295
28093505	806	817	predominant	T080	C1542147
28093505	818	827	c.315-48T	T028	C1414580
28093505	828	834	allele	T028	C0002085
28093505	848	859	splice site	T086	C1711332
28093505	899	904	T/Mut	T045	C0026882
28093505	905	913	genotype	T032	C0017431
28093505	929	932	EPP	T047	C0162568
28093505	933	941	symptoms	T184	C1457887
28093505	953	961	C allele	T028	C0002085
28093505	967	976	potential	T080	C3245505
28093505	977	983	target	T169	C1521840
28093505	988	1010	therapeutic approaches	T061	C0087111
28093505	1028	1036	splicing	T063	C0017387
28093505	1060	1065	model	T170	C3161035
28093505	1070	1090	pre-clinical studies	T062	C0013206
28093505	1127	1132	mouse	T015	C0026809
28093505	1163	1172	Fech gene	T028	C1414580
28093505	1182	1191	c.315-48C	T028	C1414580
28093505	1192	1204	polymorphism	T045	C0678951
28093505	1206	1216	F1 hybrids	T001	C0020205
28093505	1244	1248	mice	T015	C0026809
28093505	1262	1273	inbred line	T001	C1512692
28093505	1292	1296	Fech	T028	C1414580
28093505	1297	1305	mutation	T045	C0026882
28093505	1313	1318	m1Pas	T028	C1414580
28093505	1339	1342	EPP	T047	C0162568
28093505	1343	1352	phenotype	T032	C0031437
28093505	1376	1380	PPIX	T121	C0072497
28093505	1388	1393	blood	T031	C0005767
28093505	1395	1426	enlargement of liver and spleen	T033	C1112137
28093505	1428	1434	anemia	T047	C0002871
28093505	1454	1458	pain	T184	C0030193
28093505	1473	1485	skin lesions	T047	C0037284
28093505	1510	1524	light exposure	T051	C1689916
28093505	1565	1573	aberrant	T080	C0443127
28093505	1574	1585	splice site	T086	C1711332
28093505	1591	1595	mice	T015	C0026809
28093505	1648	1654	exon 3	T114,T123	C0015295
28093505	1688	1693	model	T170	C3161035
28093505	1740	1751	engineering	T090	C0014279
28093505	1757	1768	hybrid gene	T028	C0598468
28093505	1792	1804	consequences	T169	C0686907
28093505	1812	1820	splicing	T063	C0017387